Is Your Life Sciences Firm Stuck in the Middle?
Across the UK and Europe, mid-sized life sciences companies—those with revenues between $500 million and $5 billion—face a unique strategic challenge. Positioned between agile biotech startups and global pharmaceutical giants, these firms occupy what we call “the squeezed middle.”
This white paper explores the distinct pressures and opportunities facing this segment, from capital constraints and portfolio strategy to regulatory risk and operational agility. It also examines how global trade dynamics—like the Section 232 tariff review—are reshaping the landscape for supply chain, procurement, and sustainability leaders.
GET IN TOUCH WITH OUR TEAM TODAY
Interested in learning more? Reach out to Tom Wells.
